Publication
Article
Evaluating the Role of Incretin-Based Therapies in the Management of Type 2 Diabetes
This supplement to The American Journal of Managed Care reviews available comparative effectiveness research related to therapies for type 2 diabetes mellitus (T2DM); discusses differences between the glucagon-like peptide-1 (GLP-1) receptor agonists and the dipeptidyl peptidase-4 (DPP-4) inhibitors; and describes in detail the clinical evidence supporting liraglutide and its role in the treatment of T2DM.
Faculty
Andrew Ahmann, MD
Professor of Medicine
Department of Medicine: Endocrinology, Diabetes & Clinical Nutrition
Director
Harold Schnitzer Diabetes Health Center
Oregon Health & Science University
Portland, Oregon
Bruce Bode, MD, FACE
Associate Professor of Medicine
Emory University School of Medicine
Atlanta Diabetes Associates
Atlanta, Georgia
David Calabrese, RPh, MHP
Chief Clinical Officer
MedMetrics Health Partners
Assistant Clinical Professor
Bouvé College of Pharmacy and Allied Health Sciences
Northeastern University
Boston, Massachusetts
Faculty Disclosures
These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.
Andrew Ahmann, MD
Advisory board/consultant: Novo Nordisk
Grants: Amylin, GlaxoSmithKline, Lilly, Mankind, Medtronic
Honoraria/lectureship: American Diabetes Association, Lilly, Medical Education Resources, Merck
Bruce Bode, MD, FACE
Advisory board/consultant: Novo Nordisk, sanofi-aventis
Grants: GlaxoSmithKline, Lilly, Novo Nordisk
Honoraria/lectureship/conference attendance: Lilly, Novo Nordisk
David Calabrese, RPh, MHP has nothing to disclose.
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
Evaluating the Role of Incretin-Based Therapies in the Management of Type 2 Diabetes
Funding for the development of this supplement was provided by Novo Nordisk.
The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.